ReviewCell communication and signaling : CCS2025
Epigenetic orchestrator and drug enhancer: dual roles of butyrate in regulating post-translational modification and optimizing therapeutic delivery.
Review in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- ProbioticGut microbes · 2026Article
- The Metabolic Calibration of Female Immune Plasticity: From X-Linked Vulnerability to Precision Metabotyping.Biology · 2026Review
- Sodium butyrate induces mitochondrial pathway apoptosis in liver cancer via ATF4/SLC7A11-mediated ferroptosis.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Butyrate, a four-carbon short-chain fatty acid produced by gut microbiota, has been widely recognized for its diverse physiological benefits. Functioning as a natural HDAC inhibitor, it critically modulates various protein post-translational modifications (PTMs). The endogenous transport systems mediating butyrate absorption provide a promising platform for developing butyrate-modified drugs with enhanced bioavailability and tissue targeting. Here, we offer a concise overview of butyrate’s production, transport, and metabolism, focusing on its role in regulating PTMs and the potential therapeutic applications of butyrate transporters in drug delivery. Building on current butyrate modification strategies, we also review its applications in drug formulation enhancement and synergistic therapeutic combinations. In summary, butyrate can function as a natural modulator of specific PTMs and as a drug modifier enhancing therapeutic delivery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.